Autoantibodies in Immune Checkpoint Inhibitor-Related Endocrinopathies

Immune checkpoint inhibitors (ICIs) have been established as a standard treatment for many types of cancer; however, they present a clinical challenge due to unique side effects known as immune-related adverse events (irAEs). Endocrine irAEs include the more frequently reported thyroid and pituitary dysfunctions, as well as less frequent, but potentially severe conditions, such as ICI-related type 1 diabetes and primary adrenal insufficiency. These can lead to life-threatening complications, thus requiring careful management. Their pathogenesis is thought to be an autoimmune response. Recent reports have identified various autoantibodies in patients with endocrine irAEs, drawing attention to their clinical significance. This review describes the clinical features and presumed pathogenic mechanisms of endocrine irAEs. Furthermore, it comprehensively summarizes the autoantibodies reported for each endocrine irAE and discusses their significance based on the latest findings, focusing on their utility as predictive biomarkers for irAE onset, their diagnostic value, and their potential involvement in the pathogenesis.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2026-11-19
DOI
https://doi.org/10.2169/internalmedicine.8222-26
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Autoantibodies in Immune Checkpoint Inhibitor-Related Endocrinopathies

Shintaro Iwama, Hiroshi Arima, Tomoko Kobayashi
2 links
Internal Medicine
Cancer Immunotherapy and Biomarkers
article

Autoantibodies in Immune Checkpoint Inhibitor-Related Endocrinopathies

Shintaro Iwama, Hiroshi Arima, Tomoko Kobayashi
article en

Abstract

Immune checkpoint inhibitors (ICIs) have been established as a standard treatment for many types of cancer; however, they present a clinical challenge due to unique side effects known as immune-related adverse events (irAEs). Endocrine irAEs include the more frequently reported thyroid and pituitary dysfunctions, as well as less frequent, but potentially severe conditions, such as ICI-related type 1 diabetes and primary adrenal insufficiency. These can lead to life-threatening complications, thus requiring careful management. Their pathogenesis is thought to be an autoimmune response. Recent reports have identified various autoantibodies in patients with endocrine irAEs, drawing attention to their clinical significance. This review describes the clinical features and presumed pathogenic mechanisms of endocrine irAEs. Furthermore, it comprehensively summarizes the autoantibodies reported for each endocrine irAE and discusses their significance based on the latest findings, focusing on their utility as predictive biomarkers for irAE onset, their diagnostic value, and their potential involvement in the pathogenesis.

Internal Medicine
Nagoya University Hospital (JP), Nagoya University (JP)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon